GB2597291A — Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
Assigned to GW Research Ltd · Expires 2022-01-26 · 4y expired
What this patent protects
A cannabidiol (CBD) preparation for use in the treatment of seizures associated with rare epilepsy syndromes, in particular seizures associated with patients diagnosed with Batten disease. In a further embodiment, the types of seizures include absence, tonic, tonic-clonic and foc…
USPTO Abstract
A cannabidiol (CBD) preparation for use in the treatment of seizures associated with rare epilepsy syndromes, in particular seizures associated with patients diagnosed with Batten disease. In a further embodiment, the types of seizures include absence, tonic, tonic-clonic and focal seizures without impairment. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.